Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.

Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.

PMID:
30686551
2.

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.

Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP, Hurwitz H, Lenz HJ.

Br J Cancer. 2018 Apr;118(7):938-946. doi: 10.1038/s41416-018-0003-3. Epub 2018 Mar 12.

3.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.

Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8.

4.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.

Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S.

Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505.

5.

Interinstrument comparison of remote-sensing devices and a new method for calculating on-road nitrogen oxides emissions and validation of vehicle-specific power.

Rushton CE, Tate JE, Shepherd SP, Carslaw DC.

J Air Waste Manag Assoc. 2018 Feb;68(2):111-122. doi: 10.1080/10962247.2017.1296504. Epub 2018 Jan 16.

6.

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.

Mittapalli RK, Nuthalapati S, Shepherd SP, Xiong H.

Cancer Chemother Pharmacol. 2017 Mar;79(3):587-594. doi: 10.1007/s00280-017-3262-4. Epub 2017 Feb 28.

PMID:
28247011
7.

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.

Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP.

Future Oncol. 2017 Feb;13(4):307-320. doi: 10.2217/fon-2016-0412. Epub 2016 Oct 14.

8.

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).

Mizugaki H, Yamamoto N, Nokihara H, Fujiwara Y, Horinouchi H, Kanda S, Kitazono S, Yagishita S, Xiong H, Qian J, Hashiba H, Shepherd SP, Giranda V, Tamura T.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1063-72. doi: 10.1007/s00280-015-2876-7. Epub 2015 Oct 3.

9.

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.

Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, Refici-Buhr M, Chyla B, Shepherd SP, Giranda VL, Alumkal JJ.

Invest New Drugs. 2014 Oct;32(5):904-12. doi: 10.1007/s10637-014-0099-0. Epub 2014 Apr 26.

10.

The Drosophila basic helix-loop-helix protein DIMMED directly activates PHM, a gene encoding a neuropeptide-amidating enzyme.

Park D, Shafer OT, Shepherd SP, Suh H, Trigg JS, Taghert PH.

Mol Cell Biol. 2008 Jan;28(1):410-21. Epub 2007 Oct 29.

11.

Chromaffin-adrenocortical cell interactions: effects of chromaffin cell activation in adrenal cell cocultures.

Shepherd SP, Holzwarth MA.

Am J Physiol Cell Physiol. 2001 Jan;280(1):C61-71.

12.
13.

Analysis of metals in blue crabs, Callinectes sapidus, from two Connecticut estuaries.

Jop KM, Biever RC, Hoberg JR, Shepherd SP.

Bull Environ Contam Toxicol. 1997 Feb;58(2):311-7. No abstract available.

PMID:
8975810
14.

Chromaffin cell depolarization results in modulation of corticosteroidogenesis in co-culture.

Shepherd SP, Holzwarth MA.

Endocr Res. 1996 Nov;22(4):839-43.

PMID:
8969947
15.

Viraemic transmission of Crimean-Congo haemorrhagic fever virus to ticks.

Shepherd AJ, Swanepoel R, Shepherd SP, Leman PA, Mathee O.

Epidemiol Infect. 1991 Apr;106(2):373-82.

16.

Field and laboratory investigation of Crimean-Congo haemorrhagic fever virus (Nairovirus, family Bunyaviridae) infection in birds.

Shepherd AJ, Swanepoel R, Leman PA, Shepherd SP.

Trans R Soc Trop Med Hyg. 1987;81(6):1004-7.

PMID:
3140434
17.

Antibody to Crimean-Congo hemorrhagic fever virus in wild mammals from southern Africa.

Shepherd AJ, Swanepoel R, Shepherd SP, McGillivray GM, Searle LA.

Am J Trop Med Hyg. 1987 Jan;36(1):133-42.

PMID:
3101526
18.

Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa.

Swanepoel R, Shepherd AJ, Leman PA, Shepherd SP, McGillivray GM, Erasmus MJ, Searle LA, Gill DE.

Am J Trop Med Hyg. 1987 Jan;36(1):120-32.

PMID:
3101525
19.

Comparative pathogenicity and antigenic cross-reactivity of Rift Valley fever and other African phleboviruses in sheep.

Swanepoel R, Struthers JK, Erasmus MJ, Shepherd SP, McGillivray GM, Shepherd AJ, Hummitzsch DE, Erasmus BJ, Barnard BJ.

J Hyg (Lond). 1986 Oct;97(2):331-46.

20.

Comparison of techniques for demonstrating antibodies to Rift Valley fever virus.

Swanepoel R, Struthers JK, Erasmus MJ, Shepherd SP, McGillivray GM, Erasmus BJ, Barnard BJ.

J Hyg (Lond). 1986 Oct;97(2):317-29.

21.

Comparison of methods for isolation and titration of Crimean-Congo hemorrhagic fever virus.

Shepherd AJ, Swanepoel R, Leman PA, Shepherd SP.

J Clin Microbiol. 1986 Oct;24(4):654-6.

22.

A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part V. Virological and serological observations.

Shepherd AJ, Swanepoel R, Shepherd SP, Leman PA, Blackburn NK, Hallett AF.

S Afr Med J. 1985 Nov 9;68(10):733-6.

PMID:
3933129
23.

Investigations following initial recognition of Crimean-Congo haemorrhagic fever in South Africa and the diagnosis of 2 further cases.

Swanepoel R, Shepherd AJ, Leman PA, Shepherd SP.

S Afr Med J. 1985 Oct 26;68(9):638-41.

PMID:
3933132
24.

A common-source outbreak of Crimean-Congo haemorrhagic fever on a dairy farm.

Swanepoel R, Shepherd AJ, Leman PA, Shepherd SP, Miller GB.

S Afr Med J. 1985 Oct 26;68(9):635-7.

PMID:
3933131
25.

Identification of Ippy as a Lassa-fever-related virus.

Swanepoel R, Leman PA, Shepherd AJ, Shepherd SP, Kiley MP, McCormick JB.

Lancet. 1985 Mar 16;1(8429):639. No abstract available.

PMID:
2857974
26.

Protein synthesis in Rift Valley fever virus-infected cells.

Struthers JK, Swanepoel R, Shepherd SP.

Virology. 1984 Apr 15;134(1):118-24.

PMID:
6710870

Supplemental Content

Loading ...
Support Center